Literature DB >> 16284947

Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia.

William Patrick Soutter1, Peter Sasieni, Theo Panoskaltsis.   

Abstract

Invasive cancer of the cervix after treatment for cervical intraepithelial neoplasia (CIN) is becoming more important, as screening reduces the incidence of invasive disease. The rate of invasive cervical or vaginal cancer following treatment for CIN in UK remains elevated for at least 8 years. The aim of our study was to determine from international data how long this rate remains elevated and whether the rate of invasive disease reflects the rate of posttreatment CIN. The aim was to determine why the rate of invasive disease does not fall. A search of Medline and a secondary search of cited references identified 1,848 articles referring to the success rate of the treatment of CIN. Only 26 cohorts from 25 articles met all the inclusion criteria. The policy in these was to perform at least annual smears. After the first year following treatment for CIN, the rate of invasive disease remained about 56 per 100,000 woman years until at least 20 years after treatment. This rate is approximately 2.8 times greater than expected. In contrast, the risk of posttreatment CIN declined steadily with time to about 190 per 100,000 women in the 10th year. Although the posttreatment rate of CIN falls with time, the rate of invasive disease remains static. It seems likely that this is due to diminishing compliance with follow-up. Women should be encouraged to persevere with annual smears for at least 10 years after their treatment as this may offer them the best chance of detecting recurrence at a treatable stage. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16284947     DOI: 10.1002/ijc.21604

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

1.  Cervical intraepithelial neoplasia and higher long term risk of cancer.

Authors:  Guglielmo Ronco; Mario Giovanni Sideri; Stefano Ciatto
Journal:  BMJ       Date:  2007-10-24

2.  Mechanistic analysis of chemical permeation enhancers for oral drug delivery.

Authors:  Kathryn Whitehead; Samir Mitragotri
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

Review 3.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

4.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

5.  High-grade cervical lesions among women attending a reference clinic in Brazil: associated factors and comparison among screening methods.

Authors:  Neide T Boldrini; Luciana B Freitas; Amanda R Coutinho; Flavia Z Loureiro; Liliana C Spano; Angélica E Miranda
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

Review 6.  The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.

Authors:  Anne F Rositch; Heidi M Soeters; Tabatha N Offutt-Powell; Bradford S Wheeler; Sylvia M Taylor; Jennifer S Smith
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

7.  Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland.

Authors:  Maria Agapova; Andrea Duignan; Alan Smith; Ciaran O'Neill; Anirban Basu
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-09-17       Impact factor: 2.217

8.  Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment.

Authors:  Aimée R Kreimer; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Paula González; Robert D Burk; Carolina Porras; Mark E Sherman; Franklin Demuth; Li Cheung; Concepción Bratti; Ana Cecilia Rodríguez
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

9.  Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study.

Authors:  Björn Strander; Agneta Andersson-Ellström; Ian Milsom; Pär Sparén
Journal:  BMJ       Date:  2007-10-24

10.  Clinical investigation of the safety and efficacy of a cervical intraepithelial neoplasia treatment using a hyperthermia device that uses heat induced by alternating magnetic fields.

Authors:  Koji Koizumi; Toru Fujioka; Toshiaki Yasuoka; Aya Inoue; Yuka Uchikura; Hiroki Tanaka; Katsuko Takagi; Miki Mori; Masae Koizumi; Hisashi Hashimoto; Takashi Matsumoto; Yuko Matsubara; Keiichi Matsubara; Akihiro Nawa
Journal:  Mol Clin Oncol       Date:  2016-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.